Platform Trials — Beware the Noncomparable Control Group
Dodd, Lori E, Freidlin, Boris, Korn, Edward L
Published in The New England journal of medicine (22.04.2021)
Published in The New England journal of medicine (22.04.2021)
Get full text
Journal Article
Are restricted mean survival time methods especially useful for noninferiority trials?
Freidlin, Boris, Hu, Chen, Korn, Edward L
Published in Clinical trials (London, England) (01.04.2021)
Published in Clinical trials (London, England) (01.04.2021)
Get more information
Journal Article
Overall Survival As the Outcome for Randomized Clinical Trials With Effective Subsequent Therapies
KORN, Edward L, FREIDLIN, Boris, ABRAMS, Jeffrey S
Published in Journal of clinical oncology (10.06.2011)
Published in Journal of clinical oncology (10.06.2011)
Get full text
Journal Article
Reply to Quartagno et al
Freidlin, Boris, Hu, Chen, Korn, Edward L
Published in Clinical trials (London, England) (01.12.2021)
Published in Clinical trials (London, England) (01.12.2021)
Get more information
Journal Article
Randomized Phase II Trial Designs With Biomarkers
FREIDLIN, Boris, MCSHANE, Lisa M, POLLEY, Mei-Yin C, KORN, Edward L
Published in Journal of clinical oncology (10.09.2012)
Published in Journal of clinical oncology (10.09.2012)
Get full text
Journal Article
Noninferiority trials with nonadherence to the assigned randomized treatment
Korn, Edward L, Gray, Robert J, Freidlin, Boris
Published in Clinical trials (London, England) (01.12.2019)
Published in Clinical trials (London, England) (01.12.2019)
Get more information
Journal Article
Multi-Arm Clinical Trials of New Agents: Some Design Considerations
Freidlin, Boris, Korn, Edward L, Gray, Robert, Martin, Alison
Published in Clinical cancer research (15.07.2008)
Published in Clinical cancer research (15.07.2008)
Get full text
Journal Article
Design Issues in Randomized Phase II/III Trials
KORN, Edward L, FREIDLIN, Boris, ABRAMS, Jeffrey S, HALABI, Susan
Published in Journal of clinical oncology (20.02.2012)
Published in Journal of clinical oncology (20.02.2012)
Get full text
Journal Article
Blinded Independent Central Review of Progression-Free Survival in Phase III Clinical Trials: Important Design Element or Unnecessary Expense?
DODD, Lori E, KORN, Edward L, FREIDLIN, Boris, JAFFE, C. Carl, RUBINSTEIN, Lawrence V, DANCEY, Janet, MOONEY, Margaret M
Published in Journal of clinical oncology (01.08.2008)
Published in Journal of clinical oncology (01.08.2008)
Get full text
Journal Article
Gaps and opportunities in the treatment of relapsed-refractory multiple myeloma: Consensus recommendations of the NCI Multiple Myeloma Steering Committee
Kumar, Shaji, Baizer, Lawrence, Callander, Natalie S., Giralt, Sergio A., Hillengass, Jens, Freidlin, Boris, Hoering, Antje, Richardson, Paul G., Schwartz, Elena I., Reiman, Anthony, Lentzsch, Suzanne, McCarthy, Philip L., Jagannath, Sundar, Yee, Andrew J., Little, Richard F., Raje, Noopur S.
Published in Blood cancer journal (New York) (29.06.2022)
Published in Blood cancer journal (New York) (29.06.2022)
Get full text
Journal Article
Marker Sequential Test (MaST) design
Freidlin, Boris, Korn, Edward L, Gray, Robert
Published in Clinical trials (London, England) (01.02.2014)
Published in Clinical trials (London, England) (01.02.2014)
Get full text
Journal Article
Phase II Clinical Trial of Chemotherapy-Naïve Patients ≥ 70 Years of Age Treated With Erlotinib for Advanced Non–Small-Cell Lung Cancer
JACKMAN, David M, YEAP, Beow Y, FREIDLIN, Boris, OSTLER, Patricia A, LUCCA, Joan, LYNCH, Thomas J, JOHNSON, Bruce E, JDNNE, Pasi A, LINDEMAN, Neal I, FIDIAS, Panos, RABIN, Michael S, TEMEL, Jennifer, SKARIN, Arthur T, MEYERSON, Matthew, HOLMES, Alison J, BORRAS, Ana M
Published in Journal of clinical oncology (01.03.2007)
Published in Journal of clinical oncology (01.03.2007)
Get full text
Journal Article